Novo Nordisk enters deal to develop obesity therapy

Pharmaceutical Technology· Hunterframe / Shutterstock.com.
GlobalData
2 min read
3
In this article:

Novo Nordisk has entered a research partnership with Flagship Pioneering and Metaphore Biotechnologies in a joint effort to develop up to two next-generation therapeutics for the management of obesity.

The collaboration forms part of a strategic deal between Novo Nordisk and Flagship, focusing on new treatment approaches for cardiometabolic and rare diseases.

Pioneering Medicines, a division of Flagship responsible for drug development and partnerships, will lead the collaboration alongside Novo Nordisk's Bio Innovation Hub.

The Bio Innovation Hub is a research and development (R&D) unit that expedites therapeutic development through co-creation collaborations.

Metaphore will collaborate with Pioneering Medicines and Novo Nordisk to progress the programmes from foundational activities to preclinical development.

Novo Nordisk will then execute the clinical studies.

The collaboration will utilise Metaphor's MIMIC platform to create multitarget therapies that act on the GLP-1 receptor and related biology.

The goal is to develop scalable, long-acting agents that allow infrequent dosing.

Novo Nordisk may make upfront, development and commercial milestone payments of $600m, in addition to tiered royalty payments on annual net product sales.

These payments and royalties will be shared between Pioneering Medicines and Metaphore.

Novo Nordisk will reimburse R&D expenses and contribute to Metaphore’s future financing round.

Metaphore co-founder and CEO and Flagship Pioneering origination partner Lovisa Afzelius stated: “Working with Novo Nordisk is a significant opportunity to apply our MIMIC platform in one of the most exciting areas of drug development and with one of the most experienced drug development teams working in obesity.

“This collaboration could further validate our unique ability to programme function into therapeutic molecules with the MIMIC platform to enhance efficacy, extend durability and optimise manufacturing for a single therapeutic addressing multiple obesity-related targets, including but not limited to the GLP-1 receptor.”

In May 2024 Novo Nordisk reported DKr61bn ($8.7bn) in sales from its diabetes and obesity portfolio, accounting for 93.3% of its total sales in Q1 2024.

"Novo Nordisk enters deal to develop obesity therapy" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.


 


The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Advertisement

Recommended Stories

  • Pulsed field ablation poised for fast adoption, analysts say

    Feedback from the Heart Rhythm Society meeting suggests 50% to 70% of physicians could adopt the procedure “right out of the gate,” said Truist analyst Richard Newitter.

  • Serum Institute of India to acquire stake in IntegriMedical

    IntegriMedical's N-FIS technology employs a high-velocity jet stream to administer drugs and biologics.

  • Tucked Away In Pennsylvania, This Town Is America's #1 Retirement Haven

    A recent survey from GoBankingRates.com has revealed the country’s number one best place to retire. Learn where this retirement haven is and why it scored 92 on its livability index. Choosing a place to retire is an important decision to make and according to a report from the Alliance for Lifetime Income, America is soon going to be hitting its record numbers of retirement also known as the ‘silver tsunami." The report revealed that a staggering 4.1 million Americans are set to turn 65 years ol

  • Forget Nvidia: Jim Cramer Says This Company Could Be About to Cash In on Artificial Intelligence (AI) Data Centers

    Data center services are witnessing outsized demand as the AI revolution unfolds.

  • Red Lobster Chain Goes Bankrupt After Unlimited Shrimp Deal

    (Bloomberg) -- Seafood restaurant chain Red Lobster filed for bankruptcy, succumbing to onerous leases, high labor costs and a disastrous unlimited shrimp promotion. Most Read from BloombergIran State TV Says ‘No Sign of Life’ at Helicopter Crash SiteSpeedier Wall Street Trades Are Putting Global Finance On EdgeJamie Dimon Says Succession at JPMorgan Is ‘Well on the Way’One of the Last Big Bears on Wall Street Turns Bullish on US StocksHims Debuts $199 Weight-Loss Shots at 85% Discount to Wegovy

  • 'Dumb Money' Loses $13.1 Billion In Latest GameStop Stock Mania

    It appears GameStop meme investors got suckered — again. Investors who jumped into the latest online frenzy over shares of the struggling video game retailer lost $13.1 billion in just three days from the mania's high, says an Investor's Business Daily analysis of data from S&P Global Market Intelligence and MarketSurge. It's been a costly lesson for investors, some of which may have lost billions the last time on GameStop and other highly shorted stocks touted on social media.

  • Jim Cramer Destroys New Starbucks CEO In Heated Interview, Says He Was "Stunned" As Its Former CEO Admits a "Fall From Grace"

    Despite a strong start to the year for stock markets, investors in Starbucks (NASDAQ:SBUX) have been left bitterly disappointed with its shares down by approximately 20% at the time of this writing. After the earnings miss, Laxman Narasimhan, the new CEO of Starbucks, appeared on Jim Cramer's Mad Money to try and explain both the results and the company's path forward. Don't Miss: Startup behind ‘the #1 free contractor app' grows 162% YoY, opens its doors for investors at a $100 minimum. Invest

  • Microsoft delivers an AI blow to Nvidia

    The software giant goes with Nvidia's rival for a platform of AI chips.

  • Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks

    New indicators of a cooling economy eased inflation concerns, driving the S&P 500 to record highs last week. The index, which dropped around 4% in April, is now up 11% for the year. Will this momentum continue? Savita Subramanian, head of US Equity and Quantitative strategy at Bank of America, believes it will. She’s taking an upbeat stance on the current market outlook, and backs it with a look at long-term results from the past 300-plus quarters. “20 were recessionary, 13 were stagflationary,

  • Warren Buffett Says, 'When It Rains Gold, Put Out The Bucket' And These High Yield Investments Are Making It Rain

    In his 2016 letter to Berkshire Hathaway shareholders, legendary investor Warren Buffett wrote, “Every decade or so, dark clouds will fill the economic skies, and they will briefly rain gold. When downpours of that sort occur, it’s imperative that we ...